Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Apr 25, 2022 7:00 AM - Apr 27, 2022 12:00 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

DIA Your Way! Join us live in-person or live from the comfort of your home/office. This event offers two learning avenues depending on your preference!

Session 5 Track 1: Liver Targeted Therapeutics, Clinical Experience

Session Chair(s)

Louis  O'Dea, MD

Louis O'Dea, MD

Chief Medical Officer and President

BIORCHESTRA (USA) Inc, United States

Xuan  Chi, MD, PhD

Xuan Chi, MD, PhD

Supervisory Pharmacologist

CDER, FDA, United States

The speakers will present data on 3 clinical programs using liver-directed RNA therapeutic modalities. The programs will cover late phase development of a GalNAc-amended SiRNA (Inclisiran), a mid-phase GalNAc-amended ASO (Pelacarsen) and on early phase development of an LNP-formulated Crispr molecule. In addition to providing an update on the progress of each program, the session will allow the audience to compare and contrast the various programs, approaches, and challenges, and how each sponsor has found solutions that can be applied more broadly across the field of oligo therapeutics. Finally, the session is planned to allow time for fruitful exchanges between attendees and speakers.

Learning Objective :
  • Understand why oligo-based therapeutics and CRISPR-based gene editing may be uniquely suited to address certain genetic diseases
  • Understand the specific challenges of developing RNA-based therapeutics
  • Understand the challenges inherent in each of 2 different oligo-based and 1 CRISPR-based gene editing therapeutic modalities
  • Gain insight into the impact of tissue- and cell-specific targeting of these therapeutics on safety and efficacy outcomes

Speaker(s)

Tom  Thuren, MD, PhD

Inclisiran (Leqvio), a GalNAc-siRNA Anti-PCSK9 Late-phase Clinical Development and Experience From Early Post-Marketing Data: Tom Thuren, MD, PhD

Vice President

Novartis, United States

Sotirios  Tsimikas, MD

Pelacarsen, a GalNAc-ASO against Apo(a) in CVD: Phase 2 Results and Phase 3 Plan: Sotirios Tsimikas, MD

Senior Vice President, Global Cardiovascular Development

Ionis Pharmaceuticals, United States

David E Lebwohl, MD

In Vivo CRISPR/Cas9 Editing of the TTR Gene with NTLA-2001 in Patients with Transthyretin Amyloidosis: Phase 1 Results: David E Lebwohl, MD

Chief Medical Officer

Intellia Therapeutics, United States

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.